Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Dr Sands says IMforte’s lower neutropenia rate versus the prior second-line lurbinectedin trial likely reflects allowed primary G-CSF prophylaxis, not an intrinsically safer regimen. The combination still raised anemia, neutropenia, and thrombocytopenia when added to atezolizumab maintenance, so toxicity remains a real tradeoff for patients.

Related Insights

While CELMoDs frequently cause neutropenia, this effect is most pronounced in early cycles and manageable with growth factors. This contrasts sharply with the persistent, quality-of-life-impairing non-hematologic side effects of lenalidomide, such as rash and severe fatigue. This trade-off results in a significantly better long-term tolerability profile for patients.

The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.

Dr Sands says that as IMforte data matured, the tails of the progression-free and overall survival curves came together. That convergence suggests the early hazard ratios may overstate how durable the lurbinectedin maintenance benefit is over time for extensive-stage SCLC in the first-line maintenance setting.

Topoisomerase I payloads in ADCs carry a high risk of neutropenia, a toxicity that has caused previous trials to fail. Future Phase 3 studies, particularly in prostate cancer, must incorporate proactive management strategies like prophylactic GCSF to mitigate this risk, which is considered a critical success factor.

While these drugs can cause neutropenia, it rarely leads to infections. Patients often feel clinically well despite low neutrophil counts. This 'paper problem' can usually be managed with G-CSF without needing to dose-reduce the primary CLL therapy.

To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.

Data from the frontline AMPLIFY trial revealed that adding obinutuzumab to an acalabrutinib and venetoclax doublet doubled grade 3 or higher infections from 10-12% to 24%. While the triplet drove higher undetectable MRD rates, the heightened risk of neutropenia and severe infections argues against its use in older, comorbid patients.

Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.

An MD Anderson study showed that delaying the addition of obinutuzumab to an acalabrutinib-venetoclax regimen achieved similar deep remission rates (uMRD) as upfront administration. This sequencing strategy significantly reduced severe neutropenia (52% vs 12%) and infections, making the potent combination safer.

Patients receiving sacituzumab govitecan frequently face neutropenia and diarrhea, especially when heavily pretreated. Dr. Abraham recommends initiating treatment at the full 10 mg/kg dose on days one and eight, followed by dose reductions to 7.5 mg/kg or day-eight Neulastra administration to allow one recovery week.